Metazolone

# Metazolone ## Overview - **Classification**: Novel non-steroidal anti-inflammatory drug (NSAID) with immunomodulatory properties. - **Mechanism**: Selectively inhibits cyclooxygenase-3 (COX-3) and modulates intracellular signaling pathways involved in chronic inflammation. ## Primary Indications 1. **Rheumatoid Arthritis (RA)** - Moderate to severe active RA in adults. 2. **Psoriatic Arthritis (PsA)** - Active PsA in adults unresponsive to other therapies. 3. **Juvenile Idiopathic Arthritis (JIA)** - Moderate to severe JIA in patients 2 years and older. ## Adult Dosing ### Standard Dosing **Rheumatoid Arthritis / Psoriatic Arthritis** - **Dose**: **150 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: Chronic, as needed based on response and tolerability. **Acute Inflammatory Flare** (Off-label, short-term use) - **Dose**: **300 mg** - **Frequency**: Once daily for 5-7 days - **Route**: Oral - **Special Considerations**: Transition to standard dose after flare. ### Dose Adjustments - **Renal Impairment**: - CrCl **30-60 mL/min**: **75 mg** once daily. - CrCl **<30 mL/min**: Not recommended due to lack of data; consider alternative. - **Hepatic Impairment**: - Mild (Child-Pugh A): No dose adjustment. - Moderate (Child-Pugh B): **75 mg** once daily. - Severe (Child-Pugh C): Contraindicated. - **Elderly Patients**: Start with **75 mg** once daily; titrate cautiously based on renal function and tolerability. ## Pediatric Dosing ### Neonates (0-28 days) - **Metazolone is NOT recommended** in neonates due to lack of safety and efficacy data. - **Special Notes**: Potential for severe renal or GI adverse effects. ### Infants (1-12 months) - **Metazolone is NOT recommended** in infants due to limited data. - **Special Notes**: Use only if potential benefit outweighs significant risks. ### Children (1-12 years) **Juvenile Idiopathic Arthritis (JIA)** - **Age**: **2-12 years** - **Dose**: **5 mg/kg** - **Frequency**: Once daily - **Maximum**: **100 mg/dose** - **Formulation**: Oral suspension available (e.g., 25 mg/mL). - **Special Notes**: Monitor closely for GI upset and renal function. ### Adolescents (13-18 years) **Juvenile Idiopathic Arthritis (JIA)** - **Dose**: **100 mg** - **Frequency**: Once daily - **Route**: Oral - **Maximum**: **150 mg/dose** if inadequate response after 4 weeks, with close monitoring. - **Special Notes**: Transition to adult dosing guidelines at age 18. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to metazolone or NSAIDs. - **Absolute**: Active gastrointestinal bleeding or peptic ulcer disease. - **Absolute**: Severe hepatic impairment (Child-Pugh C). - **Absolute**: Severe renal impairment (CrCl <30 mL/min). - **Absolute**: Pregnancy (especially 3rd trimester) and lactation. - **Relative**: History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, dyspepsia, headache, dizziness. - **Common (1-10%)**: Diarrhea, abdominal pain, rash, peripheral edema, elevated LFTs. - **Serious but Rare**: GI perforation/bleeding, acute renal failure, severe cutaneous reactions (SJS/TEN), hepatotoxicity, cardiovascular thrombotic events (e.g., MI, stroke). ### Key Drug Interactions - **Warfarin/Anticoagulants**: Increased risk of bleeding. **Monitoring**: INR, signs of bleeding. - **Lithium**: Increased lithium levels, leading to toxicity. **Monitoring**: Lithium levels, clinical signs of toxicity. - **Diuretics/ACE Inhibitors**: Reduced antihypertensive effect, increased risk of renal impairment. **Monitoring**: Blood pressure, renal function. - **Corticosteroids**: Increased risk of GI adverse effects. **Monitoring**: GI symptoms, consider PPI. - **Other NSAIDs**: Increased risk of GI toxicity and other side effects. **Avoid concomitant use**. ## Monitoring & Follow-up - **Before Treatment**: Complete Blood Count (CBC), Liver Function Tests (LFTs), Renal Function Panel (RFP), baseline blood pressure. - **During Treatment**: - **Weekly for first month, then monthly**: LFTs and RFP. - **Periodically**: CBC (e.g., every 3 months). - **Ongoing**: Blood pressure monitoring, GI symptom assessment. - **Clinical Signs**: Watch for signs of GI bleeding (tarry stools, hematemesis), unexplained jaundice, severe skin rash, increased swelling, or signs of infection. ## Clinical Pearls - 💡 **Take with food/milk**: To minimize gastrointestinal upset. - 💡 **Hydration is key**: Ensure adequate hydration, especially in elderly or renally impaired patients, to reduce renal risk. - 💡 **Report new symptoms**: Counsel patients to report any unusual bleeding, persistent abdominal pain, dark urine, or yellowing of skin/eyes immediately. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.